Circulating microRNAs as potential biomarkers for the diagnosis of Parkinson's disease: A meta-analysis

Elbaz, 2016, Epidemiology of Parkinson's disease, Rev Neurol, 172, 14, 10.1016/j.neurol.2015.09.012 Capriotti, 2016, Parkinson disease, Home Healthc Now, 34, 300, 10.1097/NHH.0000000000000398 Tysnes, 2017, Epidemiology of Parkinson's disease, J Neural Transm (Vienna), 124, 901, 10.1007/s00702-017-1686-y Yang, 2021, Circulating microRNAs and long non-coding RNAs as potential diagnostic biomarkers for Parkinson's disease, Front Mol Neurosci, 14, 631553, 10.3389/fnmol.2021.631553 Guan, 2019, Diffusion kurtosis imaging for detection of early brain changes in Parkinson's disease, Front Neurol, 10, 1285, 10.3389/fneur.2019.01285 Tafrihi, 2019, MiRNAs: biology, biogenesis, their web-based tools, and databases, MicroRNA, 8, 4, 10.2174/2211536607666180827111633 Singh, 2017, MicroRNAs in Parkinson's disease, Exp Brain Res, 235, 2359, 10.1007/s00221-017-4989-1 van den Berg, 2020, Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders, Prog Neurobiol, 185, 101732, 10.1016/j.pneurobio.2019.101732 Emamzadeh, 2018, Parkinson's disease: biomarkers, treatment, and risk factors, Front Neurosci, 12, 612, 10.3389/fnins.2018.00612 Chen, 2017, MicroRNA-4639 is a regulator of DJ-1 expression and a potential early diagnostic marker for Parkinson's disease, Front Aging Neurosci, 9, 232, 10.3389/fnagi.2017.00232 Li, 2021, Expressions and clinical significance of miR-124 and miR-494 in elderly patients with Parkinson disease, Chin J Behav Med Brain Sci, 30, 294 Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, Ann Intern Med, 151, 264, 10.7326/0003-4819-151-4-200908180-00135 Hughes, 1992, Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases, J Neurol Neurosurg Psychiatry, 55, 181, 10.1136/jnnp.55.3.181 Marsili, 2018, Diagnostic criteria for Parkinson's disease: from James Parkinson to the concept of prodromal disease, Front Neurol, 9, 156, 10.3389/fneur.2018.00156 Whiting, 2011, QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies, Ann Intern Med, 155, 529, 10.7326/0003-4819-155-8-201110180-00009 Swets, 1988, Measuring the accuracy of diagnostic systems, Science (New York, NY), 240, 1285, 10.1126/science.3287615 Han, 2017, The diagnostic efficacy of serum miR-103a, miR-30b, miR-29a relative expression levels for Parkinson's disease, J Shandong Med, 57, 72 Zhou, 2020, The expression of serum microRNA-221 and microRNA-214 in Parkinson's disease and its correlation with Parkinson's comprehensive score, Chin Med J, 55, 206 Khoo, 2012, Plasma-based circulating microRNA biomarkers for Parkinson's disease, J Parkinson's Dis, 2, 321, 10.3233/JPD-012144 Botta-Orfila, 2014, Identification of blood serum micro-RNAs associated with idiopathic and LRRK2 Parkinson's disease, J Neurosci Res, 92, 1071, 10.1002/jnr.23377 Ding, 2016, Identification of a panel of five serum miRNAs as a biomarker for Parkinson's disease, Parkinsonism Relat Disord, 22, 68, 10.1016/j.parkreldis.2015.11.014 Dong, 2016, A panel of four decreased serum microRNAs as a novel biomarker for early Parkinson's disease, Biomarkers, 21, 129, 10.3109/1354750X.2015.1118544 Cao, 2017, MicroRNA biomarkers of Parkinson's disease in serum exosome-like microvesicles, Neurosci Lett, 644, 94, 10.1016/j.neulet.2017.02.045 Li, 2017, Plasma levels of miR-137 and miR-124 are associated with Parkinson's disease but not with Parkinson's disease with depression, Neurol Sci, 38, 761, 10.1007/s10072-017-2841-9 Sheinerman, 2017, Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases, Alzheimer's Res Ther, 9, 89, 10.1186/s13195-017-0316-0 Wu, 2020, Serum miR-9a and miR-133b, diagnostic markers for Parkinson's disease, are up-regulated after levodopa treatment, Acta Med Mediterranea, 36, 1857 Chen, 2021, Elevated plasma miR-133b and miR-221-3p as biomarkers for early Parkinson's disease, Sci Rep, 11, 15268, 10.1038/s41598-021-94734-z Li, 2021, Serum miR-214 serves as a biomarker for prodromal Parkinson's disease, Front Aging Neurosci, 13, 700959, 10.3389/fnagi.2021.700959 Lin, 2021, Diagnostic performance of miR-485-3p in patients with Parkinson's disease and its relationship with neuroinflammation, Neuromol Med Ozdilek, 2021, Serum microRNA expression levels in Turkish patients with Parkinson's disease, Int J Neurosci, 131, 1181, 10.1080/00207454.2020.1784165 Tolosa, 2021, Challenges in the diagnosis of Parkinson's disease, Lancet Neurol, 20, 385, 10.1016/S1474-4422(21)00030-2 Bloem, 2021, Parkinson's disease, Lancet, 397, 2284, 10.1016/S0140-6736(21)00218-X Deeks, 2004, Diagnostic tests 4: likelihood ratios, BMJ, 329, 168, 10.1136/bmj.329.7458.168 Zhang, 2021, The potential diagnostic accuracy of circulating microRNAs for Alzheimer's disease: a meta-analysis, Neurologia, 10.1016/j.nrl.2021.06.001